# Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

> **NCT04802057** · PHASE1 · TERMINATED · sponsor: **Bioverativ, a Sanofi company** · enrollment: 9 (actual)

## Conditions studied

- Autoimmune Haemolytic Anaemia

## Interventions

- **DRUG:** SAR445088

## Key facts

- **NCT ID:** NCT04802057
- **Lead sponsor:** Bioverativ, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-22
- **Primary completion:** 2025-03-04
- **Final completion:** 2025-03-04
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04802057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04802057, "Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04802057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*